DBV 테크놀로지스(ADR)(DBVT)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $12.35 (-1.28%), 시가총액 $1.10B, 52주 범위 $7.74 ~ $24.54.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy.
DBV 테크놀로지스(ADR)의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
DBV 테크놀로지스(ADR)의 현재 주가는 $12.35 (-1.28%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
DBV 테크놀로지스(ADR)의 시가총액은 약 $1.10B입니다.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.